Global Osteoporosis Therapeutics Industry

NEW YORK, Aug. 22, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Osteoporosis Therapeutics Industry http://www.reportlinker.com/p080451/Global-Osteoporosis-Therapeutics-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, and MAB (Denosumab). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 49 companies including many key and niche players such as Abbott Laboratories, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Servier SA, Unigene Laboratories, Inc., and Warner Chilcott plc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-3 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Bisphosphonates I-4 Hormone Replacement Therapy/Estrogen Replacement Therapy I-4 Estrogens I-4 Estrogens/Progesterones I-4 Calcitonins I-4 Selective Estrogen Receptor Modulators (SERMs) I-4 Other Therapeutics I-5

II. EXECUTIVE SUMMARY

1. OUTLOOK II-1 Generic Incursion Drubs Market Revenues Worldwide II-1 Novel Therapies to Recuperate Market Growth II-2 Denosumab Bodes Significant Market Opportunities II-2

2. MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE II-3 Bisphosphonates II-3 The leading Therapeutic Market - Only for Now II-3 ERT Drugs II-3 Ups and Downs in the ERT Market II-3 SERMs (Selective Estrogen Receptor Modulators) II-3 Market Overview II-3 Calcitonins II-4 Market Overview II-4 Monoclonal Antibodies (Denosumab) II-4 Market Overview II-4 New Drugs/Drug Classes in Pipeline II-4 End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure II-4 SERMs II-5 Eli Lilly Drops Clinical Study of Arzoxifene for Bone Loss II-6 Pfizer Intends to Withdraw NDAs for Fablyn II-6 Bisphosphonates II-6 Zoledronic Acid II-6 Pamidronate II-6 Calcitonin II-7 Emisphere's Oral Calcitonin Candidate Fails to Clear Clinical Trials II-7 Parathyroid Hormone (PTH) II-7 Novartis Terminates Clinical Study of Oral Formulation of PTH1-34 II-7 Monoclonal Antibodies - Denosumab II-7 Table 1: Comparison of Major Osteoporosis Drugs in Reducing Risk of Fracture II-8 RANK Ligand II-8 Combination Therapy II-9 Others II-9 Cathepsin K inhibitors II-9 Merck Releases New Data for Odanacatib II-9

3. MARKET DYNAMICS II-10 Facts & Figures: The Osteoporosis Primacy II-10 Snapshots II-10 Table 2: Prevalence of Osteoporosis and Osteopenia in Major Markets including US, Germany, Italy, France, UK, Spain and Japan: 2003-2013 (In Millions) (includes corresponding Graph/Chart) II-10 Osteoporosis Therapeutics: An Evolutionary Scan II-10 Currently Available Drugs for Osteoporosis Treatment II-11 "A Sketch of the Present Industry Scenario" II-11 Factors Influencing Demand II-12 Altering Competitive Landscape in Osteoporosis Market II-12 Table 3: Leading Drugs in the Global Osteoporosis Therapeutics Market (2006-2009): Value Sales for Actonel, Fosamax, Evista, Boniva, Forteo and Aclasta/Reclast in US$ Million (includes corresponding Graph/Chart) II-13

Table 4: Leading Osteoporosis Therapies and its Cost per Day II-14 Market Trends and Issues II-14 Poor Disease Detection - A Major Market Constraint II-14 Reluctance to Undergo HRT to Increase Osteoporosis Burden II-14 Patent Expiries to Impact Market Growth II-14 Limitations Bog Down Current Therapies II-15 Growth Opportunities Galore for New Drugs II-15 Bisphosphonates to Lose Market Value II-15 Poor Compliance Mars Use of Bisphosphonates II-16 Side Effects of HRT Fuel Natural Alternatives Sales II-16 Bone Formation Drugs Augur New Prospects II-16 A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics II-17 Estrogen Replacement Therapy: Will Dosing Make a Difference? II-18 Is Prevention Always Better Than Cure? II-18 Peptide-Based Osteoporosis Therapy Gaining Ground II-18 Polymorphism- A Potent Diagnostic Marker II-18 Bisphosphonates - The Other Side II-19 Efficacy of Evista under the Scanner II-19

4. PRODUCT OVERVIEW II-20 The "Silent Thief" II-20 An Introduction to Bone Physiology II-20 How Osteoporosis Steps In II-20 Osteoporosis: Major Types II-21 Primary Osteoporosis II-21 Secondary Osteoporosis II-21 Osteoporosis - The Aftermath II-22 Prevention: The Only Better Way Out II-22 Osteoporosis Therapies: A Cursory Glance II-23 Non-drug Therapy II-23 Drug Therapy II-23 Major Osteoporosis Therapeutic Classes: A Brief Review II-23 Bisphosphonates II-23 Classification of Bisphosphonates II-24 Alendronate II-24 Etidronate II-24 Risedronate II-24 Calcitonins: A Relatively Safer Therapeutic II-24 What It Is II-24 What It Does II-25 Major Types II-25 Salmon Calcitonin II-25 SERM: A Breakthrough II-25 Raloxifene: Most Widely Approved SERM II-25 SERMs: The Positive Angle II-26 SERMs: The Negative Side II-26 Hormone Replacement Therapy/Estrogen Replacement Therapy: The Longstanding Therapeutic II-26 ERT: The Positive Side II-26 The Negative Angle to ERT II-27 Tereparatide: The First Anabolic Agent II-27 Composition II-27 Forteo: A Leading Brand II-27 Major Osteoporosis Therapeutic Classes at a Glance II-27 Osteoporosis Therapeutics: A Peek into the Major Brands II-28

Follow this link:
Global Osteoporosis Therapeutics Industry